Dorzolamide

Generic name
Dorzolamide
Brand name
ATC Code
S01EC03
Compare …

Dorzolamide

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Glaucoma
  • Ocular
    • 1 month up to 18 years
      • 1 drop(s)/dose 3x daily.

      • In combination with an ophthalmological beta-blocker.

    • Term neonate
      • 1 drop(s)/dose 3x daily.

      • In combination with an ophthalmological beta-blocker.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Limited studies of ≤ 3 months duration in children (1 month – 6 years) show no safety concerns. Due to the potential risk of metabolic acidosis, neonates with significant renal tubular immaturity should receive dorzolamide only after careful benefit-risk assessment.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIGLAUCOMA PREPARATIONS AND MIOTICS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Parasympathomimetics
S01EB01
Carbonic anhydrase inhibitors
S01EC01
Beta blocking agents
S01ED01
Prostaglandin analogues
S01EE03
S01EE01
S01EE04
Other antiglaucoma preparations
S01EX
OTHER ANTIGLAUCOMA PREPARATIONS
S01EX

Reference

  1. Santen Oy, SmPC Trusopt (RVG 17618) 02-07-2021, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose